Dysregulation of the TET2/5hmC pathway promotes epithelial–mesenchymal transition (EMT), chemotherapy resistance, proliferation, invasion, and metastasis during breast cancer pathogenesis [43,44,45]. The gene discussed is TET2; the disease is breast carcinoma.